| |
Wednesday, January 15, 2025 | 12pm ET / 9am PT Sort through the noise and hear from Washington Insiders. This session will offer key insights into the economic and political landscape, guiding your company on how best to prepare for and respond to potential changes in funding opportunities and compliance requirements. Register now. 
|
|
Today’s Big NewsDec 20, 2024 |
|
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now. 
|
|
| By Nick Paul Taylor A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss targeted by executives, prompting investors to wipe 19% off the value of the Danish drugmaker. |
|
|
|
By Kevin Dunleavy With an FDA approval for Tryngolza (olezarsen) to treat the rare genetic disorder familial chylomicronemia syndrome (FCS), Ionis Pharmaceuticals enters a new era. While Ionis has gained several FDA nods in its 35 years in existence, Tryngolza will be the first medicine the Carlsbad, California-based biotech will commercialize on its own. |
By Darren Incorvaia A turbulent month at Applied Therapeutics is being capped off with the departure of CEO and chair Shoshana Shendelman, Ph.D., mere days after she and the company were named in a proposed class action lawsuit. |
By Angus Liu Merck's and GSK's similar overall survival setbacks suggest that PD-1 inhibitors may not be for ovarian cancer after all. |
|
Antibody-based therapies have transformed the treatment of many diseases, with biologics remaining at the cutting-edge of R&D today. Access this insightful resource today to explore the traditional technologies used for finding antibody hits, and the latest innovations helping to overcome the top challenges with legacy methods. Download now. 
|
|
By Conor Hale The deal, valued at about $9 million in cash to start, will see NeuroMetrix become an electroCore subsidiary—but, beforehand, the company plans to sell off its point-of-care screening test for peripheral neuropathy, DPNCheck, to add to the total proceeds. |
By Andrea Park The lack of any approved treatments that are helpful in managing both underlying inflammation and external symptoms without tacking on any major side effects has created a significant gap in the chronic hand eczema space that may be filled by up-and-coming treatments, according to a new report from GlobalData. |
By Gabrielle Masson As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate. |
By Kevin Dunleavy The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. The agency’s move means that compounding pharmacies will have to halt production of their knockoff versions of diabetes drug Mounjaro and obesity treatment Zepbound. |
By Darren Incorvaia Clinical research firm Javara has laid off staff as part of a restructuring, a spokesperson confirmed to Fierce Biotech in an email. |
By Andrea Park On the heels of Omnicom’s announcement earlier this month that it’s acquiring fellow marketing giant Interpublic Group, the head of Omnicom’s health-focused agency is stepping down. |
By Darren Incorvaia,Zoey Becker After less than a year on the job, the FDA’s principal deputy commissioner, Namandjé Bumpus, Ph.D., is leaving her post at the end of the year, according to an internal agency email reviewed by Fierce Biotech. |
By Angus Liu Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a viral capsid deal with Sangamo Therapeutics. Betta Pharma's Ensacove became the first innovative targeted lung cancer med developed by a Chinese company to win FDA approval. And more. |
By Ayla Ellison,Heather Landi This week on "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees. |
|
|---|
|
|
|
The European orphan drug market presents a significant opportunity, with forecasts predicting substantial growth in the coming years. Early access programs (EAPs) have emerged as a critical strategy for successfully launching rare disease therapies in this complex and diverse market. Access this whitepaper to learn more. 
|
|
Whitepaper We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
| |
|
